Thiazolidinediones and Cardiovascular Outcomes in Older Patients With Diabetes
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
CONTEXT: Thiazolidinediones (TZDs), used to treat type 2 diabetes, are associated with an excess risk of congestive heart failure and possibly acute myocardial infarction. However, the association between TZD use and cardiovascular events has not been adequately evaluated on a population level. OBJECTIVE: To explore the association between TZD therapy and congestive heart failure, acute myocardial infarction, and mortality compared with treatment with other oral hypoglycemic agents. DESIGN, SETTING, AND PATIENTS: Nested case-control analysis of a retrospective cohort study using health care databases in Ontario. We included diabetes patients aged 66 years or older treated with at least 1 oral hypoglycemic agent between 2002 and 2005 (N = 159 026) and followed them up until March 31, 2006. MAIN OUTCOME MEASURES: The primary outcome consisted of an emergency department visit or hospitalization for congestive heart failure; secondary outcomes were an emergency department visit or hospitalization for acute myocardial infarction and all-cause mortality. The risks of these events were compared between persons treated with TZDs (rosiglitazone and pioglitazone) and other oral hypoglycemic agent combinations, after matching and adjusting for prognostic factors. RESULTS: During a median follow-up of 3.8 years, 12 491 patients (7.9%) had a hospital visit for congestive heart failure, 12,578 (7.9%) had a visit for acute myocardial infarction, and 30 265 (19%) died. Current treatment with TZD monotherapy was associated with a significantly increased risk of congestive heart failure (78 cases; adjusted rate ratio [RR], 1.60; 95% confidence interval [CI], 1.21-2.10; P < .001), acute myocardial infarction (65 cases; RR, 1.40; 95% CI, 1.05-1.86; P = .02), and death (102 cases; RR, 1.29; 95% CI, 1.02-1.62; P = .03) compared with other oral hypoglycemic agent combination therapies (3478 congestive heart failure cases, 3695 acute myocardial infarction cases, and 5529 deaths). The increased risk of congestive heart failure, acute myocardial infarction, and mortality associated with TZD use appeared limited to rosiglitazone. CONCLUSION: In this population-based study of older patients with diabetes, TZD treatment, primarily with rosiglitazone, was associated with an increased risk of congestive heart failure, acute myocardial infarction, and mortality when compared with other combination oral hypoglycemic agent treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1990) · Choice Reviews Online · doi:10.5860/choice.27-3338 · Cited by 35,305
Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases
DEYO, R. (1992) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(92)90133-8 · Cited by 10,452 · cited 1×
“Estimated number needed to harm (95% CI)f 34 (21-52) 26 (12-105) 22 (13-47)”
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675 · cited 1×
“Estimated number needed to harm (95% CI)f 34 (21-52) 26 (12-105) 22 (13-47)”
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Diabetes and Cardiovascular Disease: The Framingham Study
Kannel, W. B. (1979) · JAMA · doi:10.1001/jama.1979.03290450033020 · Cited by 2,936
Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials
Hutchins, L. F., Unger, J. M., Crowley, J. J., Coltman, C. A., & Albain, K. S. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912303412706 · Cited by 2,174
The number needed to treat: a clinically useful measure of treatment effect
Cook, R. J., & Sackett, D. L. (1995) · BMJ · doi:10.1136/bmj.310.6977.452 · Cited by 1,885
Hux, J. E., Ivis, F., Flintoft, V., & Bica, A. (2002) · Diabetes Care · doi:10.2337/diacare.25.3.512 · Cited by 1,290
Self-citationHaffner, S. M., Greenberg, A. S., Weston, W. M., Chen, H., Williams, K., & Freed, M. I. (2002) · Circulation · doi:10.1161/01.cir.0000025403.20953.23 · Cited by 884
Booth, G. L., Kapral, M. K., Fung, K., & Tu, J. V. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68967-8 · Cited by 783
Rosiglitazone Evaluated for Cardiovascular Outcomes — An Interim Analysis
Home, P. D., Pocock, S. J., Beck-Nielsen, H., Gomis, R., Hanefeld, M., Jones, N. P., Komajda, M., & McMurray, J. J. V. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa073394 · Cited by 761
Schneeweiss, S. (2001) · American Journal of Epidemiology · doi:10.1093/aje/154.9.854 · Cited by 711
Lago, R. M., Singh, P. P., & Nesto, R. W. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61514-1 · Cited by 710
Mazzone, T., Meyer, P. M., Feinstein, S. B., Davidson, M. H., Kondos, G. T., D’Agostino, R. B., Perez, A., Provost, J.-C., & Haffner, S. M. (2006) · JAMA · doi:10.1001/jama.296.21.joc60158 · Cited by 674
Lipscombe, L. L., & Hux, J. E. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60361-4 · Cited by 626
Self-citationMultiplicative Models and Cohort Analysis
Breslow, N. E., Lubin, J. H., Marek, P., & Langholz, B. (1983) · Journal of the American Statistical Association · doi:10.1080/01621459.1983.10477915 · Cited by 565
(2003) · PubMed · Cited by 490
Stettler, C., Allemann, S., Jüni, P., Cull, C. A., Holman, R. R., Egger, M., Krähenbühl, S., & Diem, P. (2006) · American Heart Journal · doi:10.1016/j.ahj.2005.09.015 · Cited by 467
Masoudi, F. A., Inzucchi, S. E., Wang, Y., Havranek, E. P., Foody, J. M., & Krumholz, H. M. (2005) · Circulation · doi:10.1161/01.cir.0000154542.13412.b1 · Cited by 458
Lee, W. L., Cheung, A. M., Cape, D., & Zinman, B. (2000) · Diabetes Care · doi:10.2337/diacare.23.7.962 · Cited by 442 · cited 1×
“All hypoglycemic drugs (oral hypoglycemic agents and insulin) covered by the Ontario Drug Benefit program during the study period were identified and classified into 6 mutually exclusive groups: (1) TZD monotherapy (subdivided into rosiglitazone and pioglitazone); (2) other oral hypoglycemic agent monotherapy (metform…”
MethodMamdani, M., Juurlink, D. N., Lee, D. S., Rochon, P. A., Kopp, A., Naglie, G., Austin, P. C., Laupacis, A., & Stukel, T. A. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16299-5 · Cited by 435
Self-citationMethods of Cohort Analysis: Appraisal by Application to Asbestos Mining
Liddell, F. D. K., McDonald, J. C., Thomas, D. C., & Cunliffe, S. V. (1977) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2345280 · Cited by 339
Masoudi, F. A., Havranek, E. P., Wolfe, P., Gross, C. P., Rathore, S. S., Steiner, J. F., Ordin, D. L., & Krumholz, H. M. (2003) · American Heart Journal · doi:10.1016/s0002-8703(03)00189-3 · Cited by 334
Thiazolidinediones and Heart Failure
Singh, S., Loke, Y. K., & Furberg, C. D. (2007) · Diabetes Care · doi:10.2337/dc07-0141 · Cited by 262
Essebag, V., Platt, R. W., Abrahamowicz, M., & Pilote, L. (2005) · BMC Medical Research Methodology · doi:10.1186/1471-2288-5-5 · Cited by 234
Use of Thiazolidinediones and Risk of Heart Failure in People With Type 2 Diabetes
Delea, T. E., Edelsberg, J. S., Hagiwara, M., Oster, G., & Phillips, L. S. (2003) · Diabetes Care · doi:10.2337/diacare.26.11.2983 · Cited by 216
Socioeconomic Status and Mortality after Acute Myocardial Infarction
Alter, D. A., Chong, A., Austin, P. C., Mustard, C., Iron, K., Williams, J. I., Morgan, C. D., Tu, J. V., Irvine, J., Naylor, C. D., et al. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-2-200601170-00005 · Cited by 194
Self-citationReduced Screening Mammography Among Women With Diabetes
Lipscombe, L. L., Hux, J. E., & Booth, G. L. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.18.2090 · Cited by 115
Self-citationThiazolidinediones and the risk of edema: A meta-analysis
Berlie, H. D., Kalus, J. S., & Jaber, L. A. (2006) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2006.09.010 · Cited by 107
Novel Approaches to Pharmacoepidemiology Study Design and Statistical Analysis
Suissa, S. (2000) · Pharmacoepidemiology · doi:10.1002/0470842555.ch44 · Cited by 97
Pioglitazone initiation and subsequent hospitalization for congestive heart failure
Karter, A. J., Ahmed, A. T., Liu, J., Moffet, H. H., & Parker, M. M. (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01704.x · Cited by 90
Gerrits, C. M., Bhattacharya, M., Manthena, S. R., Baran, R. W., Perez, A., & Kupfer, S. (2007) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1470 · Cited by 89
Lincoff, A. M., Wolski, K., Nicholls, S. J., & Nissen, S. E. (2007) · JAMA · doi:10.1001/jama.298.10.1180 · Cited by 52
RAJAGOPALAN, R., Rosenson, R. S., FERNANDES, A., Khan, M. A., & MURRAY, F. (2004) · Clinical Therapeutics · doi:10.1016/j.clinthera.2004.09.016 · Cited by 48
Hartung, D. M., Touchette, D. R., Bultemeier, N. C., & Haxby, D. G. (2005) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.2005.25.10.1329 · Cited by 39
Long-term Risk of Cardiovascular Events With Rosiglitazone: A Meta-analysis
Singh, S., Loke, Y. K., & Furberg, C. D. (2007) · JAMA · doi:10.1001/jama.298.10.1189 · Cited by 5
Cited by
2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001063 · Cited by 4,922
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31829e8807 · Cited by 3,304
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.012 · Cited by 2,862
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31829e8776 · Cited by 2,106
Metadata
- Authors
- Lipscombe, L. L., Gomes, T., Lévesque, L. E., Hux, J. E., Juurlink, D. N., & Alter, D. A.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2007-12-12
- Volume
- 298
- Issue
- 22
- Pages
- 2634
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W1973245422
- Cited by
- 345
- References
- 40
- FWCI
- 30.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.